Stockreport

Dermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne [Yahoo! Finance]

Dermata Therapeutics, Inc.  (DRMA) 
PDF - XYNGARI™ Phase 3 STAR-1 trial enrolled 520 patients with moderate-to-severe acne in the U.S. and Latin America SAN DIEGO March 4, 2025 /PRNewswire/ -- Dermata The [Read more]